In Reply: Dr Goldstein and colleagues raise the question of whether use of statins or antidiabetic medications confounds the relationship between body mass index and pancreatic cancer survival. To answer this question, we first conducted survival analysis in 450 nondiabetic patients identified from the 609 patients who were involved in the survival analysis in our original study. We found the median survival time for normal weight, overweight, and obese patients was 18.5, 16.1, and 13.2 months, respectively (log-rank P = .28 [normal weight vs overweight] and .002 [normal weight vs obese]). Compared with normal weight patients, the hazard ratio (HR) was 1.31 (95% confidence interval [CI], 0.92-1.85) for overweight patients and 1.99 (95% CI, 1.34-1.48) for obese patients after adjusting for clinical predictors.
Li D, Hassan MM, Abbruzzese JL. Obesity and Survival Among Patients With Pancreatic Cancer—Reply. JAMA. 2009;302(16):1752-1753. doi:10.1001/jama.2009.1511